SELLAS Life Sciences Group, Inc. Deferred Revenue Recognized
SELLAS Life Sciences Group, Inc. (SLS) reported Deferred Revenue Recognized of $1.00 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2023-11-09.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2023-11-09
- SELLAS Life Sciences Group, Inc. contract with customer, liability, revenue recognized for the quarter ending 2022-03-31 was $1.00M.
| Period end | Contract with Customer, Liability, Revenue Recognized 1 month | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2022-03-31 | $1.00M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $9.50M 10-Q · filed 2023-08-10 | |||
| 2021-06-30 | -$5.60M 10-Q · filed 2021-08-12 | |||
| 2020-12-31 | $9.50M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |